Published Date: 16 Feb 2023
According to a report by the Alzheimer's Association task force, it's time to reframe what "clinically meaningful" means and change expectations about clinical trials.
Read Full NewsQ&A: Mucus Plugging, Multimorbidity, and GOLD 2027, With Gerard Criner, MD
RENEW: Blinded Interim Data Show FVC Trends With LTI-03 in IPF
Anaphylaxis Reporting Varies Across Respiratory Biologics In FAERS
Angela Lek, PhD, chief research officer at the Muscular Dystrophy Association, discussed how the 2027 MDA Clinical and Scientific Conference agenda reflects key themes in neuromuscular medicine.
In the prespecified mild subgroup of HOPE, 40-Hz gamma sensory stimulation was associated with 56% slowing on the ADCS-ADL and 47% slowing on the CDR-SB vs sham at 12 months.
Peer-reviewed results from the phase 3 X-TOLE2 trial, published in JAMA Neurology, detail azetukalner's seizure reduction and dose-dependent adverse events in adults with focal epilepsy.
The FDA approved Beren Therapeutics' adrabetadex, marketed as Lembaz, to reduce the risk of death in patients with infantile-onset Niemann-Pick disease type C.
1.
Skipping Lymph Node Biopsy Gains Ground in Breast Cancer
2.
Research has shown that Ga-68 FAPI PET enhances pancreatic cancer detection and staging.
3.
New tumor therapy approach reduces costs and side effects while increasing accessibility
4.
Temsirolimus Plus Chemotherapy Fails in Rare Childhood Cancer
5.
Alone for 500 Days, but Never Lonely: The Introvert's Dream.
1.
Hematopoietic Aging and Functional Blood Health: Mechanisms, Clinical Implications, and Advances
2.
Clinical Guidelines for Cancer-Associated Hyponatremia
3.
Spatial Tumor Mapping for Individualized Cancer Therapy
4.
Protein Degradation in Cancer: PROTACs and Targeted Degraders for Previously Difficult-to-Drug Targets
5.
Unlocking the Potential of Etoposide: A Novel Approach to Cancer Treatment
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Current Scenario of Cancer- Q&A Session to Close the Gap Part II
2.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part I
3.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
4.
Breaking Down PALOMA-2: How CDK4/6 Inhibitors Redefined Treatment for HR+/HER2- Metastatic Breast Cancer
5.
Expert Perspectives on Hematology
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation